Wilkinson ST - Search Results

1

Clinical overview of NMDA-R antagonists and clinical practice.

Davoudian PA, Wilkinson ST. Davoudian PA, et al. Among authors: wilkinson st. Adv Pharmacol. 2020;89:103-129. doi: 10.1016/bs.apha.2020.04.004. Epub 2020 Jun 1. Adv Pharmacol. 2020. PMID: 32616204 Review.

2

A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.

Wilkinson ST, Sanacora G. Wilkinson ST, et al. Drug Discov Today. 2019 Feb;24(2):606-615. doi: 10.1016/j.drudis.2018.11.007. Epub 2018 Nov 14. Drug Discov Today. 2019. PMID: 30447328 Free PMC article.

3

Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders.

Hecking J, Davoudian PA, Wilkinson ST. Hecking J, et al. Among authors: wilkinson st. Chronic Stress (Thousand Oaks). 2021 Jun 2;5:24705470211020446. doi: 10.1177/24705470211020446. eCollection 2021 Jan-Dec. Chronic Stress (Thousand Oaks). 2021. PMID: 34124495 Free PMC article. Review.

4

Long-term safety of ketamine and esketamine in treatment of depression.

Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Nikayin S, et al. Among authors: wilkinson st. Expert Opin Drug Saf. 2022 Jun;21(6):777-787. doi: 10.1080/14740338.2022.2066651. Epub 2022 Apr 19. Expert Opin Drug Saf. 2022. PMID: 35416105 Review.

5

The Role of Psychotherapy in the Management of Treatment-Resistant Depression.

Rogan T, Wilkinson ST. Rogan T, et al. Among authors: wilkinson st. Psychiatr Clin North Am. 2023 Jun;46(2):349-358. doi: 10.1016/j.psc.2023.02.006. Epub 2023 Mar 15. Psychiatr Clin North Am. 2023. PMID: 37149349 Review.

6

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.

Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. Rhee TG, et al. Among authors: wilkinson st. Drug Discov Today. 2023 Dec;28(12):103818. doi: 10.1016/j.drudis.2023.103818. Epub 2023 Nov 2. Drug Discov Today. 2023. PMID: 37925136 Review.

7

KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?

Wilkinson ST, Sanacora G. Wilkinson ST, et al. Depress Anxiety. 2016 Aug;33(8):711-7. doi: 10.1002/da.22498. Epub 2016 Apr 15. Depress Anxiety. 2016. PMID: 27082101 Free PMC article. Review.

8

Ketamine as a Treatment for Adolescent Depression: A Case Report.

Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH. Dwyer JB, et al. Among authors: wilkinson st. J Am Acad Child Adolesc Psychiatry. 2017 Apr;56(4):352-354. doi: 10.1016/j.jaac.2017.01.006. J Am Acad Child Adolesc Psychiatry. 2017. PMID: 28335880 No abstract available.

9

Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.

Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Wilkinson ST, et al. Psychother Psychosom. 2017;86(3):162-167. doi: 10.1159/000457960. Epub 2017 May 11. Psychother Psychosom. 2017. PMID: 28490030 Free PMC article. Clinical Trial.

10

Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.

van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. van Schalkwyk GI, et al. Among authors: wilkinson st. J Affect Disord. 2018 Feb;227:11-16. doi: 10.1016/j.jad.2017.09.023. Epub 2017 Sep 28. J Affect Disord. 2018. PMID: 29045915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

109 results

Search Page